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Abstract: There is no simple method to measure glomerular filtration rate (GFR) in swine, an established
model for studying renal disease. We developed a protocol to measure GFR in conscious swine by
using the plasma clearance of iohexol. We used two groups, test and validation, with eight animals
each. Ten milliliters of iohexol (6.47 g) was injected into the marginal auricular vein and blood
samples (3 mL) were collected from the orbital sinus at different points after injection. GFR was
determined using two models: two-compartment (CL2: all samples) and one-compartment (CL1:
the last six samples). In the test group, CL1 overestimated CL2 by ~30%: CL2 = 245 ± 93 and
CL1 = 308 ± 123 mL/min. This error was corrected by a first-order polynomial quadratic equation to
CL1, which was considered the simplified method: SM = −47.909 + (1.176xCL1) − (0.00063968xCL12).
The SM showed narrow limits of agreement with CL2, a concordance correlation of 0.97, and a total
deviation index of 14.73%. Similar results were obtained for the validation group. This protocol
is reliable, reproducible, can be performed in conscious animals, uses a single dose of the marker,
and requires a reduced number of samples, and avoids urine collection. Finally, it presents a
significant improvement in animal welfare conditions and handling necessities in experimental trials.
Keywords: renal function; iohexol plasma clearance; swine model
1. Introduction
Translational studies in animal models are necessary to evaluate the pathogenesis of renal disease.
Most of the basic research and preclinical studies in renal pathophysiology have been performed in mice
and rats. Rodents need reduced space, are relatively inexpensive to maintain, are easy to manage, have a
short life cycle and, in the case of mice, are easily modified by genetic engineering [1]. Thus, during the
last decades, rodents have been extensively used as models for human renal disease [2].
However, rodents do not completely recapitulate human renal disease. This has been observed
for diabetic nephropathy [3], membranous glomerulonephritis [4], and hemolytic uremic syndrome [5],
among other renal diseases. To facilitate translational research, kidney structure and function in
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animal models should be similar to that in humans. However, rodent kidneys have a single papilla
and undivided medulla and cortex. On the other hand, humans and swine share similar features of
kidney structure, function, and physiology [6–9]. Swine kidneys are multipyramidal with a cortex
and several different medullary structures; each medullary pyramid forms a separate papilla and
their fusion results in the formation of some compound papillae. Also, renal physiology is very
similar between swine and man [8], including maximal urine concentration (1080 and 1160 mOsmol/L,
respectively), maximal urine-to-plasma osmolality ratio (3.7 and 4.0), glomerular filtration rate (130 and
126–175 mL/min per 70 kg), and total renal blood flow (4 and 3.0–4.4 mL/min per gram). Hence, swine
is currently recognized as an amenable model for renal pathology [10,11].
The incidence of chronic kidney disease (CKD) and end-stage renal disease (ESRD) is increasing
worldwide [12]. Moreover, age-standardized death rates have increased by 9% for diabetes and 37% for
CKD, while those of non-communicable diseases have decreased by 18% [13]. CKD is characterized by
a progressive loss in the glomerular filtration rate (GFR). This figure may have several causes, one of
which is the lack of a reliable animal model, with an accurate method to evaluate GFR, to study CKD
and diabetic nephropathy [14]. This may help in studies on the pathogenesis of CKD and also in the
prevention of renal damage by new drugs.
GFR can be measured by the clearance of inulin, radioactively labeled markers such as 51Cr–EDTA,
125I–iothalamate, and 99mTc–DTPA (diethylene-triamine-pentaacetate), or non-radioactive markers
such as iohexol [15,16] and iothalamate. Some of these methods are complex and unpractical.
Inulin requires continuous infusion of the marker and catheterization of the bladder. The latter requires
the use of anesthesia, which could influence GFR and, therefore, alter the results of the experiment.
51Cr–EDTA and 99mTc–DTPA have the limitation of being radioactive markers. Finally, iothalamate
may be affected by the existence of tubular secretion [17,18]. The plasma clearance of iohexol has
several advantages in clinical practice and research as recently reviewed [15,16]. This method is
simple, reliable, and a safe alternative to evaluate GFR [15,16]. Iohexol is not bound by proteins,
is metabolically inert and is freely filtrated by the glomeruli; also, it is neither secreted nor metabolized
by tubular cells and has negligible extra-renal clearance [15,16,19]. Moreover, iohexol is safe even in
patients with chronic kidney disease [15,16,20].
Very few studies have evaluated the reliability of gold standard methods for evaluating GFR
in swine. The use of iohexol has been evaluated in swine [21] and compared with 51Cr–EDTA [22].
Frennby in 1997 described plasma and renal clearance of iohexol and 51Cr–EDTA in 21 anesthetized
swine. In that study, the animals were anesthetized for handling; also, urine collection and multiple
blood sampling were needed. A simplified approach to measure GFR was tested in that study, using a
correction formula designed for humans, which led to an overestimation of the true GFR. Thus, to the
best of our knowledge, there is no simple and reliable method to measure GFR in swine, which limits
the usefulness of swine as an animal model for renal disease.
The objective of this study was to develop a method using plasma clearance of iohexol to measure
renal function in conscious swine; this would reduce the number of blood samples and also take into
consideration animal welfare in accordance with Russell and Burch’s 3Rs model for animal research
(refinement, reduction, and replacement) [23].
2. Results
2.1. Iohexol Plasma Analysis
Figure 1 shows an HPLC–UV chromatogram of an iohexol-free blood sample before injection
(Figure 1A) and 120 min after injection (Figure 1B). Iohexol eluted from the chromatographic column
as two peaks at 4.03 and 4.47 min, reflecting the isomers present in the pharmacologic preparation.
The internal standard 1,3-dimethyluric acid (DMU) eluted at 6.10 min. No interfering peaks were
observed in the iohexol-free samples.
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Figure 1. Representative chromatograms of swine plasma before (A) and after (B) intravenous 
injection of iohexol (6.47 g). Iohexol isomers and internal standard (IS) 1,3-dimethyluric acid (DMU) 
were detected at 254 nm. 
2.2. Pharmacokinetic Clearance Profiles 
Figure 2 shows a two-compartment model for the iohexol plasma clearance. The first part of the 
curve, from 15 to 120 min, is curvilinear and corresponds to the distribution phase. The second part, 
from 120 to 420 min, is linear and corresponds to the elimination phase. This is why 120 min was 
selected as the starting point of the second phase (elimination phase) of the curve. Similar results 
were observed using 180 min as the starting point. 
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Figure 2. Pharmacokinetic profile of the iohexol plasma clearance considering a two-compartment 
model (CL2) in representative swine. Sampling time points are indicated by white circles (at 15, 30, 
45, 60, and 90 min) for the distribution phase and by black circles (at 120, 180, 240, 300, 360, and 420 
min) for the elimination phase. The one-compartment model (CL1) considers only the elimination 
phase. 
2.3. Test Group 
Mean GFR values were 245 ± 93 mL/min (median 229, IQR: 173–331) and 308 ± 128 mL/min 
(median 278, IQR: 221–411) for CL2 and CL1, respectively (Table 1). In all cases, GFR values 
determined by CL1 were 20–30% higher than with CL2. The recalculation of CL1 by the Bröchner–
Mortensen (BM) equation did not correct this difference. Moreover, this correction led to a systematic 
underestimation of GFR values that averaged 23% (Table 1). 
2.4. Correction Formula 
The more accurate formula to adjust CL1 to CL2 was the first-order polynomial quadratic 
equation (yi = a + bxi + cxi2; R square: 0.97) (Table S1). Applying this equation, GFR was calculated as 
follows: the simplified method SM = −47.909 + (1.176xCL1) − (0.00063968xCL12) CL1 is the clearance 
obtained based on the one-compartment model and SM the recalculated true clearance with the 
simplified method. GFR in the test group using the SM was 245.4 ± 91.4 mL/min (median: 220, IQR 
183–288), which was similar to the value obtained by CL2, which was 245.3 ± 92.8 mL/min. The error 
was less than 13% for all cases (Table 1). Individual GFR values are shown in Table 1. Finally, the 
cubic equation was not selected because the difference in GFR between CL2 and CL1 was higher than 
with the first-order polynomial quadratic formula (Table S1). 
  
Figure 2. Pharmacokinetic profile of the iohexol plasma clearance considering a two-compartment
model (CL2) in representative swine. Sampling time points are indicated by white circles (at 15, 30, 45,
60, and 90 min) for the distribution p ase and by black circles (at 120, 180, 240, 300, 360, and 420 min)
for the elimination phase. The one-compartment model (CL1) considers only the elimination phase.
2.3. Test Group
Mean GFR values were 245 ± 93 mL/min (m dian 229, IQR: 73–331) nd 308 ± 128 mL/min
(median 278, IQR: 221–411) for CL2 and CL1, respectively (Table 1). In all cases, GFR values determined
by CL1 were 20–30% higher than with CL2. The recalculation of CL1 by the Bröchner–Mortensen (BM)
equation did not correct this difference. Moreover, this correction led to a systematic underestimation
of GFR values that ave aged 23% (Table 1).
Table 1. Iohexol plasma clearance in the one- (CL1) and two-compartment (CL2) models in the test and
validati n groups. SM = si plified method. BM = Bröchner–Mortensen equation.* mL/min. ** kg.
Test Group
CASE Weight ** CL2 * CL1 * SM * SM–CL2 (%) BM * BM–CL2 (%)
1 113 119.6 150.4 114.6 −4.2 121.5 1.6
2 122 172.6 236.3 194.3 12.5 166.1 −3.8
3 138 225.8 301.6 248.7 10.1 188.1 −16.7
4 132 233.8 255.4 210.8 −9.9 173.6 −25.8
5 101 175.8 216.4 176.7 0.5 157.4 −10.5
6 210 341.8 433.1 341.4 −0.1 200.6 −41.3
7 209 300.5 345.6 282.1 −6.1 196.9 −34.5
8 212 392.0 527.4 394.4 0.6 183.7 −53.1
mean ± SD 155 ± 47 245 ± 93 308 ± 123 245 ± 91 190 ± 26
Validation Group
Weight ** CL2 * CL1 * SM * SM–CL2 BM * BM–CL2
9 106 173.7 213.7 174.2 0.3 156.1 −10.2
10 182 246.8 275.9 227.9 −7.7 180.7 −26.8
11 116 112.1 128.0 92.2 −17.8 106.9 −4.7
12 159 289.9 394.6 316.6 9.2 201.3 −30.6
13 156 202.8 253.5 209.1 3.1 172.9 −14.8
14 176 289.6 331.2 271.4 −6.3 194.5 −32.8
15 115 202.8 257.7 212.7 4.9 174.4 −14.0
16 188 313.9 360.9 293.2 −6.6 198.9 −36.6
mean ± SD 150 ± 33 229 ± 69 277 ± 85 225 ± 71 181 ± 31
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2.4. Correction Formula
The more accurate formula to adjust CL1 to CL2 was the first-order polynomial quadratic equation
(yi = a + bxi + cxi2; R square: 0.97) (Table S1). Applying this equation, GFR was calculated as follows:
the simplified method SM = −47.909 + (1.176xCL1) − (0.00063968xCL12) CL1 is the clearance obtained
based on the one-compartment model and SM the recalculated true clearance with the simplified
method. GFR in the test group using the SM was 245.4 ± 91.4 mL/min (median: 220, IQR 183–288),
which was similar to the value obtained by CL2, which was 245.3 ± 92.8 mL/min. The error was
less than 13% for all cases (Table 1). Individual GFR values are shown in Table 1. Finally, the cubic
equation was not selected because the difference in GFR between CL2 and CL1 was higher than with
the first-order polynomial quadratic formula (Table S1).
2.5. Validation Group
The mean GFR values were 229 ± 69 (median: 181, IQR 225–290) mL/min and 277 ± 85 mL/min
(median: 267, IQR 224–353) for CL2 and CL1, respectively (Table 1). Applying the Bröchner–Mortensen
equation to CL1 led to a 19% underestimation of GFR. On the other hand, GFR assessed by SM was
225 ± 71 mL/min (median: 350, IQR 210–311), which was similar to the value obtained by CL2
(229 ± 69 mL/min), showing an error less than 10% for almost all animals (Table 1). Individual GFR
values are shown in Table 1.
2.6. Analysis of Agreement
The Bland–Altman plot (Figure 3) shows narrow limits of agreement (from −30.6 to 34.9 mL/min)
and a mean difference of 2.1 mL/min between values measured with the simplified method (SM) and
the reference method (CL2), indicating good agreement.
Compared with the reference method (CL2), the simplified method (SM) had a concordance
correlation coefficient (CCC) of 0.97 (0.94, upper confidence interval (CI), reflecting high precision and
accuracy. Also, the total deviation index (TDI) was 14.73% (20.62), which means that 90% of the GFR
values showed an error ranging from −14.7 to +14.7% when compared with the reference method.
Finally, the coverage probability (CP) was 71 (54), which indicates that more than 29% of the GFR
values had an error range greater than ±10% of the method in plasma.Int. J. Mol. Sci. 2018, 19, 232 6 of 12 
 
 
Figure 3. The Bland–Altman plot of the difference between the glomerular filtration rate (GFR) values 
measured by the reference method (two-compartment clearance: CL2) and simplified method (SM) 
versus the mean of both. The straight and dashed lines indicate mean difference and 95% limits of 
agreement, respectively. 
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2.8. Sensitivity Analysis 
The results of CL1 were comparable using the starting point of the elimination phase at 120 or 
180 min. 
2.9. Calibration and Quality Control Standards 
The differences between the experimental back-calculated concentrations of the calibration 
standards and the theoretical levels were within ± 5% for all the analyses. The deviations for the low- 
and high-quality controls were always lower than 7.5%. 
3. Discussion 
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includes the following steps: (i) administering 6.47 g iohexol through an intravenous catheter placed 
at the marginal auricular vein; (ii) collecting six blood samples at 120, 180, 240, 300, 360, and 420 min 
after the iohexol injection; (iii) determining plasma iohexol concentrations by HPLC–UV; (iv) 
calculating the best fitting curve for these concentrations by a slope–intercept method; (v) calculating 
iohexol plasma clearance as the ratio of dose over area under the curve; and (vi) correcting the 
obtained value by a formula. 
Our method was performed in swine with normal GFR, paving the way for future studies in 
animals with reduced GFR. However, the applicability of the method should not depend on the level 
of GFR. The mathematical approach will be the same for animals with normal, supranormal, or 
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2.7. Reproducibility Study
The mean absolute percentage error for the replicas in the overall group was 9.3% (Table S2).
2.8. Sensitivity Analysis
The results of CL1 were comparable using the starting point of the elimination phase at 120 or
180 min.
2.9. Calibration and Quality Control Standards
The differences between the experimental back-calculated concentrations of the calibration
standards and the theoretical levels were within ± 5% for all the analyses. The deviations for the low-
and high-quality controls were always lower than 7.5%.
3. Discussion
The present study offers a new, simple, reliable, and reproducible method using plasma clearance
of iohexol to measure glomerular filtration rate (GFR) in swine. This method uses a specific correction
formula applied to a one-compartment model of pharmacokinetic analysis. The procedure includes
the following steps: (i) administering 6.47 g iohexol through an intravenous catheter placed at the
marginal auricular vein; (ii) collecting six blood samples at 120, 180, 240, 300, 360, and 420 min after
the iohexol injection; (iii) determining plasma iohexol concentrations by HPLC–UV; (iv) calculating
the best fitting curve for these concentrations by a slope–intercept method; (v) calculating iohexol
plasma clearance as the ratio of dose over area under the curve; and (vi) correcting the obtained value
by a formula.
Our method was performed in swine with normal GFR, paving the way for future studies in
animals with reduced GFR. However, the applicability of the method should not depend on the
level of GFR. The mathematical approach will be the same for animals with normal, supranormal,
or reduced GFR, as it is in humans [15,16]. Such a hypothesis is supported by the previous studies of
Bröchner–Mortensen [24] who developed a formula in Caucasian patients that has subsequently been
applied for all levels of renal function in many studies.
This new proposed protocol has major advantages: it is performed in conscious animals with
no movement restrictions, it uses a single dose of the marker, it requires a reduced number of blood
samples (n = 6), and it avoids urine collection. This represents a significant improvement in animal
welfare conditions and handling necessities in experimental trials that require the evaluation of GFR.
Importantly, our method eliminates the influence of sedation or anesthesia on GFR [25,26].
For the selection of new methods in research with animal models, sampling techniques
must be reproducible and simple. Our method provides a simple and reliable approach for GFR
measurement in swine, using only blood sample extractions. Urine sampling can be used in swine
but implies catheterization of the urinary tract, which is technically difficult and requires the use
of anesthetics [27–29].
The clearance of inulin is considered the gold standard method in the measurement of GFR.
However, this method is neither simple nor practical, particularly in large animals. On the other hand,
plasma clearance of iohexol has shown good correlation with the clearance of inulin [15,16]. In our
method, urine collection is not necessary. This is a major simplification since the collection of urine
is complicated in these animals. In swine, Frenbby et al. [21] reported a difference of 4.0 mL/min
per 10 kg weight between renal and plasma clearances of iohexol. In this study, the last sample for
calculating GFR was collected at 270 min, which may have influenced the results. The number and the
timing for the last sample in multiple-sample approaches are fundamental to achieving acceptable
precision and accuracy. The later the last sample is collected, the better is the concordance between
renal and plasma clearances of iohexol [16]. In our study, the last sample was taken at 420 min,
which may have led to a better agreement between our method and the urinary clearance of iohexol.
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In any case, urine collection would make the whole procedure much more complex and difficult
to perform.
The plasma clearance of iohexol was originally described in 1984 in humans [30] and since then
it has been frequently used in clinical research. Iohexol is a stable molecule, which is freely filtrated
through the glomeruli; it is not metabolized by tubular cells and is completely eliminated in the
urine [31]. Moreover, the procedure is very safe with few and minor side effects having been reported.
Plasma clearance of iohexol is based on the disappearance curve of the marker, which typically fits a
two-compartment model with an initial rapid reduction (distribution phase) followed by a slow and
linear decline in plasma concentration (elimination phase). One-compartment models are focused only
on the elimination phase, which has the advantages of limiting the number of samples for estimating
GFR and improving animal welfare, handling necessities, and cost efficiency. However, this approach
does not take into account the early distribution phase, which is a source of errors, making the use of a
corrective formula necessary [24]. A previous study in swine [21] used a formula developed in humans,
the Bröchner–Mortensen equation, to correct for the clearance derived from the one-compartment
model [24]. However, this adjustment did not improve the performance of the simplified method.
The formula of Bröchner–Mortensen was developed in humans in whom the values of GFR ranged
from 0 to 120 mL/min [24]. In our study, the GFR values of the swine were two times higher or even
more and this may be the reason why the Bröchner–Mortensen formula is not accurate in swine. In our
study, we firstly evaluated a two-compartment model, which was considered as the reference method.
The clearance obtained using the values of the elimination phase led to a 20–30% overestimation of
the true GFR measured by the reference method. Then, we developed a correction formula to adjust the
clearance of the elimination phase to the reference method. This simplified method importantly reduced
the error to less than 10%.
Finally, we tested the agreement between the values of GFR obtained by the simplified method
and the two-compartment model. The results of the Bland–Altman test, as well as the TDI and CCC,
showed good agreement, which allows the use of this method in swine to evaluate GFR.
4. Material and Methods
4.1. Ethics Statement
The study was performed according to the Spanish Policy for Animal Protection RD1201/05,
which meets the European Union Directive 86/609 about the protection of animals used in research.
The experiment was specifically assessed and approved (report CEEA 2012/012, 28/01/2012) by the
Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA) Committee of Ethics
in Animal Research, which is the named Institutional Animal Care and Use Committee (IACUC)
for the INIA. The sows were housed at the animal facilities of the INIA, which meet local, national,
and European requirements for Scientific Procedure Establishments.
4.2. Experimental Design
We used two groups of animals (test and validation) involving a total of 16 female adult Iberian
swine (8 to 10 years old); each group was formed by eight animals. The animals were conscious
throughout the experiment, were restrained only for sampling for 3 to 5 min, and were free to move
throughout the experiment. No sedation or anesthesia was used for the sampling procedure.
At 8:00 a.m., after 6–8 h of fasting, a single dose of 10 mL Omnipaque 300 (GE Healthcare,
Madrid, Spain) containing 6.47 g iohexol was injected for 2 min through the marginal auricular vein
of one ear. We selected a single dose of 10 mL since it is the same dose we use in humans [15,16].
We prefer to avoid an infusion of the marker since this procedure would need the use of sedation or
anesthesia. After injection, blood samples (3 mL) were taken at 15, 30, 45, 60, 90, 120, 180, 240, 300, 360,
and 420 min and collected in EDTA-treated tubes. This protocol was based on Frennby et al. [21] with
some modifications: samples were reduced from 16 extractions to 11 for the two-compartment model,
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and to six for the one-compartment model (see below). Blood samples were taken from the orbital
sinus. Phlebotomy can be difficult in swine since there are few viable sites from which to draw blood;
surface veins are small and the use of deep veins such as the cava and jugular is technically complex,
which increases discomfort and the risk for bleeding, especially in big animals. Blood collection from
the orbital sinus is an established technique in veterinary practice described in 1969 and is minimally
invasive and simple [32,33]. Also, animals exhibit little discomfort and return to their activities after
the procedure is completed.
A blank (iohexol-free) blood sample was collected at time zero before the marker was administered.
Blood samples were immediately centrifuged at 2000× g for 15 min and plasma was stored at −80 ◦C
in the biobank.
4.3. Iohexol Measurements
Iohexol plasma concentrations were measured by HPLC–UV as previously reported [34].
Briefly, 200 µL of plasma was added to 50 µL of the internal standard (IS) 1,3-dimethyluric acid
(DMU) (500 mg/mL) and deproteinized with 750 µL of 5% perchloric acid. Samples were vortexed
and centrifuged for 5 min at 12,500 rpm. A 5 µL aliquot of supernatant was chromatographed by a
C18 reversed-phase column (5 mm, 150 × 4.6 mm, Advanced Chromatography Technologies Ltd.,
Aberdeen, UK) using an HPLC system (Agilent Series 1260 Infinity, Santa Clara, CA, USA) equipped
with a diode array detector set at 254 nm. Iohexol isomers were eluted by a mixture of deionized
water/acetonitrile (96:4 by volume, adjusted to pH 2.5 with phosphoric acid) pumped at a flow rate of
1.0 mL/min. The calculations of the concentrations of iohexol were performed using the height of the
peak of the second isomer of iohexol compared with the IS peak (peak height ratio).
4.4. Calibration and Quality Control Standards
Internal calibration curves of iohexol were prepared for each set of samples. A working solution
of iohexol (647 µg/mL) was prepared in deionized water and used for the calibration curve and quality
control samples. A total of five concentrations of iohexol (32.35, 64.7, 97.05, 129.4, and 161.75 µg/mL in
plasma) were used as calibrators. Two quality control standards (QCs) prepared in-house, containing
iohexol at low (64.7 µg/mL) and high (129.4 µg/mL) concentrations, were also prepared and used for
validation tests. Calibrators, quality control samples, and reference standard solutions were stored at
−20 ◦C until use.
4.5. Pharmacokinetic Analyses: One- and Two-Compartment Models
a. Two-compartment model (CL2): in the test group the concentrations of iohexol at 15, 30, 45, 60,
90, 120, 180, 240, 300, 360, and 420 min were fitted by nonlinear regression analysis to calculate the
area under the curve (AUC). The iohexol plasma clearance was calculated as the ratio between the
dose of iohexol and the AUC (dose/AUC).
b. One-compartment model (CL1): in the test group only the elimination phase, which starts
at 120 min after injection of the marker, was considered. Then, the concentrations of iohexol at
120, 180, 240, 300, 360, and 420 min were fitted by a slope–intercept method to determine the AUC.
The slope–intercept method considers data only of the slow exponential and the fit is done by taking
the natural logarithm of the plasma concentrations (Pi). The linear regression of ln(Pi) against the
time (ti) was performed to determine the slope (–k) and the intercept (ln(P0)). The AUC of the single
exponential is given by AUC = (P0)/k. The iohexol plasma clearance was determined as the ratio
dose/AUC.
4.6. Developing a Correction Formula to Simplify the Method
GFR calculated by CL1 overestimated true GFR assessed by CL2 (Table 1). The one-compartment
model (CL1) underestimated the AUC because it did not consider the initial distribution phase of iohexol.
Thus, a formula was needed to recalculate the true clearance. Based on a previous publication [21],
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we tested the Bröchner–Mortensen equation to adjust the values of CL1. Different equations were
developed to recalculate CL1 using linear and nonlinear regression models. The best equation was
selected based on the highest R2. This equation was considered as the simplified method (SM) to
measure GFR using the plasma clearance of iohexol. In the validation group, we calculated CL2 and
CL1 and applied the SM as described above.
4.7. Reproducibility Study
The reproducibility of the plasma clearance of iohexol was determined in an extra group of
12 animals (2 to 3 years old) in which the method was performed two times, separated by seven days.
We calculated the absolute difference of the method using the mean absolute percentage error.
4.8. Sensitivity Analysis
To evaluate the validity of the initial time point of the elimination phase, GFR was calculated
considering the starting point at 120 min and at 180 min.
4.9. Pharmacokinetic Analysis
Results were expressed as mean ± SD. The fit between CL1 and CL2 was evaluated with
several regression models: linear, logarithmic, inverse, quadratic, cubic, compound, power, S-curve,
exponential, and logistic. All data were fitted by a nonlinear regression iterative program. The best
equation was selected based on the higher R square and the lower differences between CL2 and CL1.
The formula was applied to CL1 and this was considered the simplified method (SM) for the iohexol
plasma clearance. Calculations and graphical representation were performed with SPSS Statistics for
Windows, version 17.0 (SPSS Inc., Chicago, IL, USA).
4.10. Statistical Analysis: Tests of Agreement
The agreement between CL2 and SM was assessed by the limits of agreement described by
Bland and Altman [35] and the total deviation index (TDI), concordance correlation coefficient (CCC),
and coverage probability (CP) as proposed by Lin et al. [36]. The limits of agreement are a simple
graphic tool which describes the limits that include the majority of the differences between two
measurements. The narrower these limits are, the better the agreement. CCC combines elements of
accuracy and precision. Its scores range from 0 to 1 and a value > 0.90 reflects optimal concordance
between measurements. TDI is a measure that captures a large proportion of data within a boundary
for allowed differences between two measurements [36]. CP ranges from 0 to 1; it is a statistic that
estimates whether a given TDI is less than a pre-specified percentage [37]. The ideal situation is to
have a TDI <10%, meaning that 90% of the estimations fall within an error of ±10% from the gold
standard. Finally, these statistics provide confidence intervals that allow generalization of the results.
For the Bland and Altman test, we used the MedCalc statistical software, version 15.8 (MedCalc
Software bvba, Ostend, Belgium). For the agreement analyses, we used the statistical package AGP
(Agreement Program) version 1.0 (IGEKO, SP) available at: http://lfr.ecihucan.es/apps/agreement_
installer/Agreement_Installer.exe. The AGP is based on the R code originally developed by Lawrence
Lin and YuYue [37]. The AGP was developed to simplify the use of the tool given in the R agreement
package (R Core Team (2017). R: A language and environment for statistical computing. R Foundation
for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/.5.
5. Conclusions
In conclusion, we have developed a simplified method to measure renal function in swine.
This method is simple, reproducible and reliable, accurate and precise, requires a reduced number of
blood samples, and improves animal management and welfare. Moreover, this new method facilitates
sequential measurements of renal function, which allows the assessment of changes in GFR over time.
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Finally, the proposed protocol is similar to the one used in clinical research in humans, which could
facilitate translational studies.
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/19/1/232/s1.
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